# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>COURY ROBERT J</u>						2. Issuer Name and Ticker or Trading Symbol MYLAN INC. [ MYL ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner						
(Last)	(F YLAN BLV	(First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 02/27/2015									X Officer (give title below) Other (specific below)  Executive Chairman					
(Street) CANONSBURG PA 15317					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting						
(City) (State) (Zip)					tive Securities Acquired, Disposed of, or Benefic									Person						
1. Title of	Security (Ins		ole I - Noi	2. Trans			2A. De		3.		4. Securit	ties Acqu	ired (A	) or	5. Amou Securitie	nt of	6. Ov		7. Nature of Indirect	
				(Month/Day/Y			if any			Code (Instr.			Of (D) (Instr. 3, 4 and		Beneficial Owned F Reported	ally Following d	(D) or Indirect (I) (Instr. 4)	r Indirect str. 4)	Beneficial Ownership (Instr. 4)	
				00/0	02/27/2015				Code	v	Amount	(D)		Price	Transaction(s) (Instr. 3 and 4)					
Common Stock <sup>(1)(2)</sup> 02/27				//201	2015			D		1,276,6	5,690 D		(3)		0		D	By		
Common Stock <sup>(1)(2)</sup> 02/27/2				7/201	2015			D		4,957	4,957 D		(3)		0		I	401(k) Plan		
			Table II -						uired, D s, optior						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transaction Code (Instr. 8)		of		6. Date Exercisab Expiration Date (Month/Day/Year)		of Securiti		rities ing ve Sec	urity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	or Nu of	nount mber ares						
Employee Stock Option - Right to Buy <sup>(4)</sup>	\$21.13	02/27/2015			D			14,196	(5)	(	3/03/2020	Commo Stock	<sup>n</sup> 14	,196	(4)	0		D		
Employee Stock Option - Right to Buy <sup>(4)</sup>	\$22.66	02/27/2015			D			4,413	(6)	(	3/02/2021	Commo Stock	<sup>n</sup> 4,	413	(4)	0		D		
Employee Stock Option - Right to Buy <sup>(4)</sup>	\$23.44	02/27/2015			D			4,266	(7)	(	12/22/2022	Commo Stock	<sup>n</sup> 4,	266	(4)	0		D		
Employee Stock Option - Right to Buy <sup>(4)</sup>	\$30.9	02/27/2015			D			3,236	(8)	(	3/06/2023	Commo Stock	n 3,	236	(4)	0		D		
Employee Stock Option - Right to	\$55.84	02/27/2015			D			58,952	(9)	(	3/05/2024	Commo Stock	<sup>n</sup> 58	,952	(4)	0		D		

# **Explanation of Responses:**

- 1. On February 27, 2015 (the "Closing Date"), Mylan N.V. completed the transaction (the "Transaction") by which it acquired Mylan Inc. and Abbott Laboratories' ("Abbott") non-U.S. developed markets specialty and branded generics business (the "Business"). Pursuant to the terms of the Amended and Restated Business Transfer Agreement and Plan of Merger, dated as of November 4, 2014, by and among Mylan Inc., New Moon B.V. (which has been renamed Mylan N.V. and is referred to herein as "Mylan"), Moon of PA Inc. ("Merger Sub"), and Abbott, on the Closing Date, Mylan acquired the Business and Merger Sub merged with and into Mylan Inc., with Mylan Inc. surviving as a wholly owned indirect subsidiary of Mylan and each share of Mylan Inc. common stock issued and outstanding was cancelled and automatically converted into and became the right to receive one Mylan ordinary share (the "Merger"). (Continued in Footnote 2)
- 2. In connection with the Transaction, Mylan Inc. and the Business have been reorganized under Mylan, a new public company organized in the Netherlands. This report is being filed by the reporting person solely to report the disposition of shares of Mylan Inc. common stock in connection with the Transaction. The reporting person will file a separate Form 4 to reflect the corresponding acquisition of securities of Mylan in connection with the Transaction.
- 3. Represents shares of Mylan Inc. common stock that were exchanged on a one-for-one basis for Mylan ordinary shares in connection with the Transaction. On the effective date of the Merger, the closing price of MYL was \$57.33 per share
- 4. Represents stock options of Mylan Inc. common stock that were exchanged for stock options of Mylan ordinary shares having substantially the same terms in connection with the Transaction.
- 5. These options vested on March 3, 2013.

- 6. These options vested on March 2, 2014.
- 7. These options vested on February 22, 2015.
- 8. These options vest on March 6, 2016.
- 9. These options vest in three equal annual installments beginning on March 5, 2015.

# Remarks:

/s/ Bradley L. Wideman, by power of attorney 02/27/2015

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.